分享产品介绍 评论(0)
物种
Human抗原名称
EphA2分子别名
ECK, MPK-5, MPK5, SEK-2, SEK2, Myk2Accession
P29317-1表达序列
Ala24-Val537, with C-terminal 10*His Tag表达宿主
HEK293分子量
55-70kDa
纯度
>95% by SDS-PAGE内毒素含量
<0.1EU/μg标记
Unconjugated标签
His Tag性状
Lyophilized Powder缓冲体系
PBS, pH7.4
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
文献引用
1. Ping Zhao. EphA2: A promising therapeutic target in breast cancer. J Genet Genomics. 2021 Apr 20;48(4):261-267. Epub 2021 Mar 29.
Ephrin type-A receptor 2 (EphA2), a receptor tyrosine kinase, is overexpressed in human breast cancers often linked to poor patient prognosis. Accumulating evidence demonstrates that EphA2 plays important roles in several critical processes associated with malignant breast progression, such as proliferation, survival, migration, invasion, drug resistance, metastasis, and angiogenesis. As its inhibition through multiple approaches can inhibit the growth of breast cancer and restore drug sensitivity, EphA2 has become a promising therapeutic target for breast cancer treatment.
电泳
1μg (R: reducing condition, N: non-reducing condition).
ELISA
Immobilized EphA2 His Tag, Human (Cat. No. UA010580) at 2μg/mL (100μL/well) can bind Ephrin-A1 Fc Chimera Protein, Human (Cat. No. UA011030) with EC50 of 0.70-1.00 ng/ml.
评论(0)